despit
year
research
contribut
type
ifn
control
spread
initi
immunolog
damag
remain
controversi
viral
infect
effici
stimul
host
antivir
defens
respons
product
type
ifn
induct
larg
set
isg
fail
keep
viru
entir
check
strikingli
distressingli
patient
prolong
exposur
type
ifn
chronic
phase
infect
associ
desensit
andor
detriment
hyperimmun
activ
contribut
diseas
progress
appar
paradox
action
ifn
infect
also
wellestablish
chronic
hcv
infect
major
patient
unabl
clear
viru
develop
viral
persist
face
rapidli
induc
isg
respons
parallel
chronic
hcvinfect
patient
strong
isg
express
treat
ribavirin
virolog
respons
rare
moreov
viral
infect
clear
sustain
type
ifn
signal
seem
assum
predominantli
immunosuppress
role
possibl
limit
host
toxic
morbid
persist
infect
inde
direct
causal
link
type
ifn
signal
immun
activ
neg
immun
regul
express
eg
lymphoid
tissu
disorgan
impair
humor
respons
secondari
viral
infect
persist
lcmv
report
thu
emerg
evid
show
type
ifn
common
nexu
pathogenesi
chronic
viral
diseas
interestingli
type
ifn
shown
caus
immunopatholog
andor
neg
effect
even
acut
viral
infect
eg
influenza
sever
acut
respiratori
syndromeassoci
coronaviru
sever
bacteri
infect
given
grow
evid
type
ifn
involv
viral
diseas
progress
surpris
possibl
target
either
type
ifn
mechan
lead
ifn
product
diseas
consid
promis
new
therapeut
approach
howev
complex
ifn
system
immunopathogenesi
make
clinic
consequ
manipul
type
ifn
signal
difficult
predict
vivo
therapeut
intervent
therefor
approach
caution
posit
subject
inde
sever
key
question
controversi
role
play
type
ifn
control
infect
remain
unansw
despit
intens
research
area
review
attempt
address
issu
summar
current
knowledg
type
ifn
respons
play
dual
role
replic
diseas
progress
emphasi
place
import
type
ifn
subtyp
signatur
strategi
ifn
evas
host
genet
interplay
ifn
microbiom
main
factor
affect
magnitud
ifn
respons
infect
ifn
system
consist
broad
famili
cytokin
key
player
develop
innat
adapt
immun
respons
accord
cellular
origin
type
receptor
bind
ifn
group
three
differ
type
tabl
type
ifn
compris
multipl
speci
signal
heterodimer
receptor
ifna
receptor
ifnar
human
sever
subtyp
one
one
one
one
particular
exclud
pseudogen
least
distinct
subtyp
genet
structur
similar
lack
intron
protein
sequenc
highli
conserv
amino
acid
sequenc
ident
cluster
short
arm
chromosom
unclear
advantag
mani
differ
subtyp
provid
vitro
antivir
antiprolif
activ
subtyp
vari
effect
innat
adapt
immun
differ
among
subtyp
may
reveal
variat
affin
ifna
receptor
variabl
signal
complement
receptor
type
furthermor
depend
cell
type
kind
stimul
subtyp
pattern
express
regul
differenti
express
variou
ifn
regulatori
factor
irf
despit
differ
subtyp
mainli
produc
pdc
fibroblast
main
sourc
one
bodi
best
natur
weapon
virus
recognit
specif
receptor
type
ifn
trigger
jakstat
pathway
lead
express
hundr
isg
isg
encod
protein
may
limit
spread
infect
affect
host
andor
viral
pathway
eg
retrovir
restrict
factor
moreov
innat
adapt
immun
cell
respond
type
ifn
enhanc
antigen
present
chemokin
product
increas
antibodi
product
b
cell
amplifi
effector
function
cell
unlik
multipl
type
ifn
type
ii
ifn
includ
singl
cytokin
mainli
secret
lymphocyt
nk
cell
bind
heterodimer
receptor
coordin
wide
array
cellular
program
transcript
regul
immunolog
relev
gene
type
iii
ifn
recent
identifi
class
belong
ifn
system
includ
four
subtyp
among
type
iii
ifn
express
product
control
dinucleotid
polymorph
known
locat
exon
protein
produc
individu
carri
function
genet
variant
allel
share
featur
type
ifn
famili
display
type
ifnlik
antivir
activ
induct
classic
isg
function
similar
result
activ
common
signal
pathway
although
engag
specif
receptor
complex
compos
also
known
accessori
chain
tissuerestrict
express
type
ifn
liver
tissu
epitheli
cell
highli
sensit
action
infect
usual
acquir
sexual
mucos
transmiss
studi
simian
immunodefici
viru
siv
intravagin
infect
macaqu
demonstr
siv
multipl
initi
confin
mucos
infect
site
follow
transmiss
eclips
phase
day
viru
initi
incresead
mucos
site
local
lymphoid
tissu
system
spread
begin
context
primat
model
demonstr
cytokin
respons
includ
ifn
product
earlier
stronger
mucos
tissu
genit
tract
lower
system
lymphoid
tissu
vagin
siv
inocul
particular
ifn
antivir
chemokin
seem
produc
local
pdc
recruit
mucos
site
within
h
siv
exposur
later
siv
spread
lymphoid
tissu
associ
strong
product
site
lymph
node
pdc
major
exclus
produc
mediat
transient
respons
acut
phase
siv
infect
inde
administr
antagonist
impact
siv
load
acut
respons
plasma
minim
effect
isg
express
blood
lymph
node
indic
cell
may
involv
process
eg
monocytesmacrophag
myeloid
dc
similarli
ifn
mediat
eg
induc
within
week
prior
peak
viremia
acut
infect
likewis
siv
infect
rhesu
macaqu
peripher
blood
jejunum
express
sever
ifninduc
restrict
factor
substanti
increas
cell
memori
subset
peak
acut
infect
alongsid
induct
type
ifn
ifnrel
pathway
robust
increas
prr
record
acut
siv
infect
peripher
blood
gut
mucosa
coincid
viral
replic
pronounc
respons
induc
acut
infect
may
also
detriment
effect
contribut
initi
control
viral
replic
also
immunopatholog
infect
howev
neg
effect
type
ifn
becom
evid
chronic
phase
infect
inde
diseas
progress
occur
serum
increas
regular
concentr
compar
acut
phase
correl
occurr
antigen
serum
moreov
differ
express
profil
type
ifn
pathway
cell
record
earli
infect
infect
less
month
chronic
progressor
infect
year
latter
suggest
stereotyp
ifn
pattern
gene
express
cell
might
establish
earli
infect
persist
year
thereaft
like
infect
human
pathogen
siv
infect
nonnatur
host
speci
rhesu
macaqu
associ
robust
type
ifn
respons
isg
express
persist
sivinfect
macaqu
even
though
pdc
partial
deplet
blood
andor
lymph
node
contrast
nonpathogen
siv
infect
african
green
monkey
sooti
mangabey
display
strong
pdc
activ
type
ifn
product
acut
siv
infect
low
activ
chronic
infect
intriguingli
pdc
level
capabl
sens
siv
releas
type
ifn
nonpathogen
siv
infect
seem
decreas
acut
infect
furthermor
sivinfect
sooti
mangabey
intrins
resist
type
ifn
signal
conclud
mechan
involv
capabl
anim
retain
low
immun
activationinflamm
expect
multifactori
exclus
depend
ifnisg
stimul
agreement
result
obtain
primat
model
siv
infect
sever
studi
ifn
inhibit
releas
rt
viral
antigen
product
releas
whole
hiv
virion
effect
amount
cellassoci
viral
protein
report
strong
activ
differ
compon
associ
type
ifn
respons
eg
irf
isg
viral
dna
sensor
ifnar
chronic
infect
high
level
isg
also
associ
rapid
cell
deplet
consist
find
signific
isg
upregul
observ
virem
nonprogressor
global
tcell
gene
express
profil
ifnrel
gene
nonprogressor
appear
similar
infect
notion
ifn
pathway
increas
persist
replic
also
support
observ
larg
isg
group
downregul
lymph
node
biopsi
sampl
posthaart
therapi
moreov
interrupt
haart
accompani
increas
mucos
gene
express
ifnmedi
antivir
respons
profil
similar
found
naiv
infect
patient
although
prolong
antiretrovir
treatment
improv
galt
immun
function
type
ifn
respons
gut
seem
persist
longterm
treat
patient
find
could
due
rapid
pdc
migrat
intestin
lymphoid
tissu
acut
siv
infect
caus
local
inflamm
type
ifn
product
complex
seemingli
paradox
role
type
ifn
infect
well
document
pronounc
type
ifn
respons
induc
infect
may
likewis
detriment
effect
although
ifn
produc
infect
abl
inhibit
earli
infect
persist
ifnmedi
immun
activ
becom
one
main
pathogen
mechan
diseas
contrari
administr
initi
upregul
express
isg
prevent
system
infect
pathogen
siv
rhesu
macaqu
model
use
intrarect
challeng
suggest
posit
action
ifn
control
earli
viral
infect
howev
treatment
also
result
acceler
cell
deplet
increas
viremia
probabl
due
activ
ifnrel
desensit
mechan
induc
continu
treatment
henc
type
ifn
respons
infect
discuss
could
exert
posit
neg
effect
indic
dual
role
regul
promot
infect
immunopathogenesi
sever
group
demonstr
type
ifn
inhibit
replic
human
cell
cultiv
vitro
studi
identifi
multipl
mechan
type
ifn
affect
infecti
cycl
determin
target
cell
time
ifn
addit
viru
infect
tabl
particular
treatment
primari
lymphocyt
monocytesmacrophag
cell
line
infect
effici
suppress
earli
step
viru
life
cycl
includ
cell
fusion
viral
rna
dna
protein
product
tabl
howev
appear
mechan
type
ifn
inhibit
replic
cell
macrophag
ident
princip
effect
ifn
infect
cell
primari
lymphoblast
cultur
termin
stage
life
cycl
eg
assembl
releas
morphogenesi
ifn
macrophag
appear
interrupt
earli
step
replic
cycl
tabl
moreov
monocyt
treat
type
ifn
week
infect
free
retrovir
pathogen
level
provir
dna
ifntreat
control
hivinfect
cell
indistinguish
similarli
ifninduc
inhibit
viral
protein
synthesi
could
detect
cell
cell
treat
prior
infect
ad
h
postinfect
ad
later
stage
replic
cycl
infect
alreadi
establish
also
impair
later
stage
replic
cycl
especi
persist
infect
cell
cultur
rang
deregul
viral
protein
process
protein
stabil
impair
incorpor
morphogenesi
alter
virion
releas
howev
effect
chronic
infect
seem
much
less
pronounc
high
concentr
ifn
case
exceed
intern
unitsml
use
experi
sinc
effect
absent
neglig
dose
shown
effect
major
lytic
virus
moreov
longterm
efficaci
ifn
spread
cell
measur
follow
gagexpress
cell
seem
less
potent
inhibit
particular
gradual
increas
percentag
cell
time
observ
cell
expos
high
dose
viru
emerg
result
suboptim
suppress
moltipl
celltocel
transfer
moder
sensit
type
ifn
thu
molecular
natur
inhibit
ifn
appear
cell
type
depend
multipl
paramet
like
infecti
dose
time
ifn
addit
subtyp
ifn
use
experi
care
consid
interpret
result
situat
exemplifi
observ
subtyp
within
type
ifn
strongli
suppress
replic
multipl
stage
infect
addit
close
relat
lentivirus
appear
inhibit
type
ifn
differ
stage
express
cell
tabl
highlight
complex
phenomenon
togeth
limit
emphas
risk
extrapol
result
obtain
vitro
condit
clinic
applic
patient
explain
part
vitro
antihiv
potenc
ifn
gener
contrast
poor
clinic
efficaci
sever
mechan
propos
explain
neg
action
type
ifn
patient
fig
first
type
ifn
could
partli
trigger
chronic
immun
activ
induc
isg
chemokin
abl
attract
target
cell
initi
site
replic
regard
siv
macaca
model
show
induct
endocerv
mucos
signal
system
involv
also
known
product
virusinhibit
chemokin
pdc
cell
creat
environ
rich
target
cell
cell
cell
site
initi
infect
cytokin
growth
factor
review
second
role
apoptosi
immunopathogenesi
propos
particular
trail
product
depend
mediat
antibodi
block
trail
product
apoptosi
expos
cell
produc
pdc
respons
trail
express
primari
cell
importantli
increas
mrna
express
trail
record
tonsil
patient
progress
diseas
compar
tonsil
patient
nonprogress
diseas
upregul
trail
express
also
observ
posit
patient
high
level
isg
eg
viremia
besid
relationship
apoptosi
chronic
infect
proapoptot
bak
found
increas
cell
correl
posit
sensit
apoptosi
neg
cell
number
moreov
model
cellintrins
type
ifn
signal
due
microbi
exposur
recent
propos
potenti
gut
cell
acceler
inhibit
cyclin
cmyc
third
report
viral
infect
highli
potent
immunosuppress
program
mediat
reduc
cell
respons
might
respons
harm
effect
also
chronic
infect
lastli
relationship
type
ifn
thymopoiesi
hivinduc
immunodefici
state
observ
thymu
dysfunct
known
character
infect
contribut
pathophysiolog
human
thymu
thymocyt
medullari
pdc
constitut
express
type
ifn
suppress
thymic
output
limit
cell
recoveri
strong
alter
chemokin
subtyp
transcript
pattern
sivinfect
thymus
also
record
subtyp
produc
infect
thymus
inhibit
thymocyt
prolifer
moreov
infect
human
thymu
result
increas
level
associ
mhc
upregul
thymic
epitheli
cell
subsequ
preferenti
select
thymocyt
low
level
express
may
contribut
gener
immunosuppress
express
also
induc
thymic
organ
cultur
suggest
may
paradox
expand
tropism
enhanc
viral
infect
infect
patient
welldocu
type
ifn
andor
isg
might
exert
deleteri
effect
infect
although
actual
relationship
ifn
respons
infect
still
matter
debat
inde
differenti
effect
age
gender
host
genet
immun
environ
cell
type
overal
outcom
type
ifn
signal
infect
remain
unexplain
also
unknown
main
type
ifn
subtyp
express
acut
chronic
hiv
infect
translat
studi
need
establish
magnitud
effect
microbiom
composit
ifn
activ
individu
lastli
becom
import
understand
impact
mechan
refractori
type
ifn
activ
infect
main
factor
affect
type
ifn
respons
infect
discuss
provid
evid
detail
role
pictur
antagon
type
ifn
product
antivir
respons
strongli
support
concept
ifn
innat
potenti
control
infect
vitro
type
ifn
inhibit
infect
mani
isg
eg
retrovir
restrict
factor
strong
antihiv
potenc
howev
abl
replic
vivo
even
presenc
type
ifn
isg
though
mechan
abl
persist
remain
mysteri
known
inadequaci
transmiss
across
mucos
surfac
illustr
stringent
popul
bottleneck
one
limit
number
variant
improv
transmiss
fit
divers
quasispeci
transmit
donor
abl
start
new
infect
regard
tf
virus
seem
phenotyp
distinct
increas
type
ifn
resist
key
featur
elucid
abil
replic
spread
effici
despit
potent
mucos
innat
immun
respons
moreov
tf
virus
uniformli
resist
ifitm
requir
lost
chronic
infect
part
due
escap
mutat
acquir
respons
autolog
neutral
respons
besid
demonstr
tf
virus
overcom
antivir
action
specif
isg
sever
vitro
studi
shown
inhibit
type
ifn
induct
mainli
interact
irf
member
three
import
target
cell
cell
macrophag
dc
remark
multipl
evas
strategi
employ
block
type
ifn
induct
action
fig
particular
evolv
use
host
cofactor
cyclophilin
recuit
capsid
cloak
moltiplact
permit
evas
prr
cga
type
ifn
secret
initi
antivir
state
defect
innat
viral
sens
infect
involv
prr
cga
induc
express
inhibit
activ
vpu
moreov
impair
tlr
respons
record
infect
also
affect
prrmediat
signal
inhibit
sever
downstream
effector
includ
level
andor
activ
follow
type
ifn
product
also
subvert
mechan
action
fig
specif
stimul
product
molecular
inhibitor
ifn
signal
impair
phosphoryl
moreov
downregul
ifnar
express
consequ
hyporespons
pbmc
patient
record
although
specif
evas
mechan
employ
current
undefin
lastli
sever
isg
block
includ
wellestablish
antivir
protein
eg
pkr
oa
recent
identifi
retrovir
restrict
factor
eg
controversi
result
report
abil
type
ifn
directli
induc
restrict
factor
name
howev
besid
establish
abil
subvert
activ
vpx
gene
regul
type
ifn
treatment
phosphoryl
threonin
respons
direct
induct
henc
clear
order
replic
effici
evolv
multipl
strategi
circumv
first
line
defens
embodi
type
ifn
probabl
antivir
effector
activ
infect
degre
circumv
viru
strategi
nevertheless
mode
action
isg
remain
unclear
strategi
requir
allow
circumv
particular
ifn
respons
determin
mechan
isg
function
differ
step
replic
cycl
viruscel
interplay
subsequ
reshap
host
defens
mechan
would
interest
gain
complet
understand
molecular
basi
host
interact
immunopathogenesi
diseas
differ
host
factor
age
gender
specif
molecular
pattern
cell
environ
could
affect
magnitud
type
ifn
activ
infect
howev
rel
influenc
infect
remain
poorli
understood
despit
limit
mark
sex
differ
type
ifn
express
describ
cours
diseas
particular
pdc
women
shown
exhibit
stronger
respons
ligand
pdc
men
caus
higher
secondari
activ
cell
express
level
subset
isg
includ
mxa
also
found
higher
naiv
infect
femal
male
adjust
rna
level
associ
elev
level
immun
activ
infect
studi
attempt
character
influenc
patient
age
product
type
ifn
demonstr
agerel
dysregul
capac
synthes
ifn
isg
siv
infect
far
genom
studi
type
ifn
concern
major
problem
high
number
gene
eg
pseudo
gene
differ
subtyp
numer
type
ifn
signal
pathway
compon
isg
howev
sever
studi
point
import
snp
relat
type
ifn
pathway
clinic
outcom
diseas
rapid
progress
infect
alter
viral
load
cell
count
associ
polymorph
genet
variat
common
among
individu
high
peak
viral
load
compar
lowmoder
peak
viral
load
snp
prr
gene
ie
involv
genom
sensor
also
identifi
exhaust
genotyp
gene
french
aid
cohort
disclos
protein
variant
associ
aid
progress
suscept
infect
addit
snp
associ
progress
infect
aid
identifi
two
gene
eg
contrast
snp
identifi
gene
gene
associ
slower
progress
diseas
sever
studi
report
controversi
result
influenc
retrovir
restrict
factor
snp
eg
diseas
statu
although
clinic
relev
genet
variant
infect
emphas
biolog
signific
seldom
examin
regard
two
snp
locat
intronextron
boundari
significantli
associ
decreas
level
product
pdc
respons
furthermor
effect
snp
locat
within
region
exon
sequenc
express
patient
record
besid
analysi
genet
variant
relat
ifn
respons
patient
studi
look
type
iii
ifn
snp
far
attract
much
attent
hcv
research
genomewid
associ
studi
identifi
associ
certain
snp
locat
upstream
region
spontan
ifn
treatmentinduc
viral
clearanc
chronic
hcv
infect
interestingli
origin
snp
identifi
near
posit
within
intron
gene
encod
newli
discov
importantli
snp
report
affect
isg
product
particularli
liver
hcvinfect
patient
daa
therapi
discord
result
obtain
clinic
signific
snp
infect
one
hand
snp
associ
unfavor
clinic
immunolog
statu
increas
suscept
cytomegaloviru
retin
protect
diseas
progress
control
snp
effect
clinic
outcom
suscept
infect
far
biolog
signific
type
iii
ifn
snp
infect
concern
consid
type
iii
ifn
share
jakstat
pathway
endogen
isg
express
pbmc
patient
seem
independ
dinucleotid
polymorph
despit
mani
indic
type
ifn
signatur
infect
predomin
type
ifn
speci
perhap
subtyp
upregul
patient
conclus
determin
one
oldest
studi
histori
ifn
report
acidlabil
human
leukocyt
ifn
homosexu
men
kaposi
sarcoma
lymphadenopathi
high
level
also
detect
sera
patient
type
ifn
subtyp
analyz
provid
quantit
comparison
one
first
studi
topic
done
gendelman
et
al
examin
express
monocyt
howev
mani
year
later
shown
main
type
ifn
measur
peripher
blood
subject
although
latter
work
report
elev
express
infect
extent
subtyp
upregul
investig
attempt
made
tackl
issu
recent
year
particular
preferenti
upregul
subtyp
express
record
posit
patient
use
pigtail
macaqu
siv
model
zaritski
et
al
also
demonstr
subtyp
express
regul
differ
brain
lung
spleen
furthermor
respons
oral
pathogen
siv
infect
multipl
subtyp
quickli
induc
lymphoid
mucos
surfac
oral
gastrointestin
tract
recent
nextgener
sequenc
studi
also
analyz
express
subtyp
pdc
found
subtyp
mrna
centromer
half
ifna
gene
cluster
highli
express
pdc
follow
exposur
invers
relationship
subtyp
express
potenc
record
potent
block
infect
highli
express
exhibit
rel
weak
antivir
activ
agreement
subtyp
shown
possess
potent
activ
compar
subtyp
gene
therapi
plasmid
encod
commonli
use
confer
longterm
suppress
replic
human
mous
model
thu
follow
new
concept
emerg
studi
induc
differ
express
pattern
type
ifn
subtyp
ii
product
individu
subtyp
differ
relat
cell
type
anatom
site
analyz
ii
differ
subtyp
mediat
distinct
effect
indirectli
suggest
differ
type
ifn
prepar
might
provid
differ
therapeut
outcom
infect
known
earli
infect
initi
main
pronounc
deplet
cell
gener
occur
gastrointestin
mucosa
elev
level
cell
within
gut
may
permit
entri
replic
chronic
infect
within
gastrointestin
tract
close
relat
secondari
decreas
cell
significantli
shape
gut
physiolog
thu
lead
dysregul
mucos
immuneepitheli
network
addit
direct
role
chang
gastrointestin
cell
compart
wide
establish
infect
character
gut
microbiom
composit
function
chang
gori
et
al
first
studi
gut
microbiota
earli
phase
infect
found
high
abund
pseudomona
aeruginosa
candida
albican
well
lower
level
microbi
speci
eg
bifidobacteria
lactobacilli
fecal
microbiota
compar
report
healthi
individu
nevertheless
exact
microbiom
configur
naiv
individu
haarttreat
patient
healthi
subject
remain
still
inconsist
first
attempt
briefli
describ
gut
microbiom
composit
infect
patient
discuss
emerg
novel
concept
concern
interact
gut
microbiota
ifn
immun
respons
previou
studi
indic
infect
impact
intestin
microbiota
composit
given
infect
associ
enhanc
bacteri
popul
gut
proinflammatori
potenti
pathogen
whose
abund
parallel
inflammatori
statu
immun
recoveri
fig
major
find
gut
microbiota
composit
infect
patient
adapt
cytokin
growth
factor
review
particular
despit
consider
experiment
variabl
eg
type
sampl
evalu
treat
treat
subject
techniqu
use
character
microbiota
main
find
investig
follow
first
infect
associ
reduc
bacteri
rich
particular
diminut
divers
observ
subject
compar
uninfect
subject
mucos
fecal
sampl
greater
fecal
microbi
divers
record
msm
nonmsm
importantli
reduct
bacteri
rich
persist
even
patient
stratifi
msm
vs
nonmsm
decreas
divers
posit
correl
cell
count
invers
correl
marker
microbi
transloc
monocyt
activ
surprisingli
haart
result
signific
chang
gut
microbiota
toward
increas
henc
benefici
gut
microbiom
divers
alter
bacteri
commun
composit
typic
observ
domin
phyla
detect
proxim
gut
proteobacteria
bacteroidet
firmicut
fig
context
overal
enrich
member
phylum
proteobacteria
decreas
abund
firmicut
observ
mucos
tissu
stool
sampl
untreat
treat
infect
individu
unexpectedli
signific
decreas
abund
firmicut
observ
hivinfect
patient
use
nrti
pi
compar
uninfect
control
suggest
specif
haart
regimen
associ
divers
profil
gut
microbiota
composit
famili
level
rel
abund
prevotellacea
seem
higher
infect
subject
wherea
lachnospiracea
christensenellacea
ruminococcacea
bacteroidacea
lower
infect
subject
rel
uninfect
individu
furthermor
bacteria
evalu
genu
level
enrich
burkholderia
acinetobact
schigella
klebsiella
salmonella
rahnella
observ
infect
patient
fig
contrast
lactobacillu
within
firmicut
phylum
reduc
duoden
tissu
naiv
posit
individu
higher
lactobacillu
abund
also
found
fecal
sampl
cohort
untreat
subject
earli
infect
higher
count
lower
viral
load
reduc
microbi
transloc
interestingli
associ
continu
follow
haart
altough
difficult
draw
definit
conclus
appear
posit
patient
microbiota
character
increas
potenti
pathogen
bacteria
convers
decreas
protect
bacteria
popul
howev
underlin
complet
definit
well
healthi
microbiota
still
incomplet
given
myriad
factor
influenc
composit
gut
microbiom
sinc
gut
microbiota
exhibit
immunemodul
qualiti
consid
compon
microbiota
directli
contribut
cell
deplet
infect
regul
gut
helper
subsetrel
immun
homeostasi
tempt
specul
better
character
complex
interact
microbi
dysbios
mucos
immun
system
critic
improv
understand
function
aspect
microbiom
key
addit
driver
diseas
known
crosstalk
gut
microbiom
host
extens
involv
innat
adapt
immun
establish
infect
upset
delic
equilibrium
hostmicrob
interplay
alter
gut
microbiom
see
interfer
host
respons
mechan
regard
report
endogen
type
ifn
respons
induc
signal
commens
microbiota
affect
local
signal
environ
prime
intestin
mucos
immun
system
determin
later
respons
pathogen
commens
organ
howev
yet
determin
microbiota
dysbiosi
patient
could
influenc
local
andor
system
innat
antivir
immun
respons
includ
type
ifn
product
also
associ
express
known
use
specif
receptor
preferenti
express
mucos
surfac
context
remark
dampen
prr
express
recent
observ
gut
mucos
tissu
acut
chronic
siv
infect
rhesu
macaqu
decreas
prr
express
associ
increas
abund
numer
pathogen
bacteri
taxa
includ
pasteurellacea
member
aggregatibact
actinobacillu
mycoplasmatacea
famili
turn
might
respons
promot
persist
ifn
activ
gut
microbiota
alter
limit
viral
clearanc
despit
reduc
express
prr
microbi
exposur
influenc
alter
gut
cell
transcriptom
caus
strong
upregul
type
ifn
isg
product
surprisingli
induct
multipl
antivir
gene
microbi
exposur
also
associ
enhanc
tf
replic
agreement
previou
studi
record
strong
activ
receptor
gut
mucosa
subject
moreov
preliminari
observ
suggest
link
microbiota
composit
type
ifn
signatur
patient
unpublish
data
studi
emphas
dysregul
isg
level
observ
infect
could
least
part
determin
specif
microbiota
composit
hypothesi
support
follow
recent
find
first
commens
bacteria
calibr
activ
threshold
innat
antivir
immun
particular
tonic
signal
type
ifn
antigenpres
cell
requir
effici
viral
recognit
gener
adapt
immun
signal
provid
commens
bacteria
steadi
state
second
type
ifn
receptor
function
intestin
epitheli
cell
restrain
paneth
goblet
cell
shape
microbi
composit
third
bacteri
microbiom
foster
enter
viral
persist
eg
noroviru
manner
counteract
specif
compon
innat
immun
system
eg
type
iii
ifn
nice
besid
abil
microbiota
modul
ifn
respons
yet
unclear
mechan
specif
compon
enter
microbiota
ie
microbi
metabolit
desaminotyrosin
shown
exert
distal
effect
respons
lethal
viral
infect
modul
type
ifn
thu
bacteri
product
modul
differ
compon
innat
immun
system
potenti
facilit
respons
microbi
pathogen
work
requir
defin
specif
mechan
bacteria
andor
metabolit
well
microorgan
eg
virom
mycom
might
impact
ifn
signal
immun
intestin
also
anatom
site
wellestablish
type
ifn
direct
andor
indirect
induct
sever
mediat
benefici
effect
innat
adapt
immun
cell
viral
infect
known
howev
low
level
type
ifn
may
requir
earli
stage
initi
cellmedi
immun
respons
high
concentr
may
lead
product
immunosuppress
molecul
type
ifninduc
viru
protect
immunopatholog
autoimmun
also
seem
matter
kinet
magnitud
particular
delay
type
ifn
product
implic
promot
viral
diseas
tempt
specul
viral
infect
clear
persist
type
ifn
activ
assum
princip
immunosuppress
role
probabl
reduc
host
toxic
chronic
infect
type
ifninduc
neg
regulatori
pathway
repres
one
major
driver
persist
inflammationimmun
activ
diseas
progress
chronic
viral
infect
caus
hcv
howev
role
type
ifn
chronic
viru
infect
complex
often
lead
differ
outcom
depend
time
host
cellular
environ
present
cumul
amount
type
ifn
compon
specif
ifn
subtyp
mediat
biolog
effect
suggest
viral
diseas
balanc
network
type
ifn
exist
provid
protect
minimum
damag
host
still
larg
unknown
inde
although
wide
knowledg
varieti
signal
pathway
activ
ifn
system
link
specif
pathway
distinct
outcom
wellunderstood
especi
complex
viral
diseas
infect
regard
observ
elev
type
ifn
signatur
deleteri
chronic
infect
togeth
difficulti
encount
vivo
manipul
type
ifn
signal
prompt
us
reflect
whether
properli
investig
therapeut
potenti
clinic
set
instanc
sinc
first
use
earli
promis
therapi
start
therapi
patient
regardless
whether
preexist
elev
type
ifn
signatur
could
render
patient
intrins
resist
ifn
therapi
therefor
veteran
lesson
isgmedi
resist
ifn
therapi
hcv
infect
wrong
evalu
compar
siv
effect
without
first
assess
endogen
level
type
ifn
activ
moreov
indiffer
target
type
ifn
pathway
without
take
account
individu
variat
ifn
gene
express
pattern
eg
type
ifn
subtyp
isg
etc
achiev
would
import
advanc
thoroughli
explor
infect
mani
factor
also
consid
interpret
data
activ
type
ifn
respons
infect
sever
issu
yet
address
exampl
studi
evalu
type
ifn
respons
infect
analyz
isg
respons
although
isg
product
may
somehow
reflect
direct
activ
type
ifn
respons
disregard
isg
also
induc
ifnindepend
mechan
eg
directli
virus
type
ifnscytokin
eg
analysi
ifn
respons
infect
also
gener
perform
classic
innov
molecular
techniqu
hide
real
contribut
protein
express
epigenet
regul
ifn
gene
addit
confound
factor
correct
interpret
role
ifnisg
infect
lastli
real
contribut
ifn
type
subtyp
eg
natur
histori
infect
microbiom
regul
rate
type
iiii
ifn
activ
current
unknown
henc
essenti
understand
ifn
mechan
induct
action
detail
studi
factor
affect
kinet
magnitud
ifn
respons
acut
chronic
viral
infect
inform
help
us
provid
addit
insight
type
ifn
paradox
infect
essenti
har
power
product
natur
benefit
